TG THERAPEUTICS
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 264
- Market Cap
- $3.5B
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 277
- Registration Number
- NCT03801525
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Seattle, Washington, United States
🇺🇸TG Therapeutics Investigational Site, Louisville, Kentucky, United States
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03778073
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Seattle, Washington, United States
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT03671590
- Locations
- 🇵🇱
TG Therapeutics Investigational Trial Site, Wrocław, Poland
An Extension of the TG1101-RMS201 Trial
- Conditions
- Interventions
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03381170
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, San Antonio, Texas, United States
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
- Conditions
- Interventions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT03379051
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Cleveland, Ohio, United States
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03364231
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, New York, New York, United States
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
- Conditions
- Interventions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 549
- Registration Number
- NCT03277261
- Locations
- 🇺🇸
TG Therapeutics RMS Investigational Site, Round Rock, Texas, United States
🇺🇸TG Therapeutics RMS Investigational Trial Site, Dallas, Texas, United States
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 545
- Registration Number
- NCT03277248
- Locations
- 🇺🇸
TG Therapeutics RMS Investigational Trial site, Seattle, Washington, United States
🇺🇸TG Therapeutics RMS Investigational Trial Site, Pittsburgh, Pennsylvania, United States
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT03207256
- Locations
- 🇺🇸
TG Therapeutics Investigational Site, Canton, Ohio, United States
🇺🇸TG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin, United States
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 710
- Registration Number
- NCT02793583
- Locations
- 🇬🇧
TG Therapeutics Investigational Trial Site, Plymouth, United Kingdom